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rug-Eluting Stents for
cute Myocardial Infarction*
. Vernon Anderson, MD, FACC,†
ichard W. Smalling, MD, PHD, FACC,†
imothy D. Henry, MD, FACC‡
ouston, Texas; and Minneapolis, Minnesota
ith recent hysteria regarding late thrombosis of drug-
luting stents (DES) now apparently subsiding, it may be
seful to pause, reflect for a moment, and consider some
ecent pertinent results regarding their wider use. These
ew results arise from the sphere of DES for percutaneous
oronary intervention (PCI) in acute ST-segment elevation
yocardial infarction (STEMI). Clinical trials of DES
howed they reduce the rates of restenosis and target vessel
evascularization compared with bare-metal stents (BMS)
n elective PCI (1,2). This reduction appears to be especially
otent for PCI of chronic occlusions (3), an important
omparator. It was logical for clinicians to believe that DES
ould be superior to BMS in the STEMI setting too. But
he needed randomized clinical trial data until now were
acking. Early reports of registry data had been unequivo-
ally encouraging. Lemos et al. (4) in 2004 reported results
n 186 consecutive STEMI patients treated with DES,
ompared with 183 STEMI patients treated with BMS.
See page 1924
ollow-up at 300 days revealed reduction in target vessel
evascularization (TVR) (1.1% vs. 8.2%, p 0.01) as well as
eduction in major adverse cardiovascular events (MACE)
9.4% vs. 17%, p 0.02) in favor of DES. Mortality though
as not different (8.3% vs. 8.2%). Newell et al. (5) in 2006
eported results on 306 consecutive STEMI patients who
eceived a DES (n  156) or a BMS (n  150). Follow-up
t 6 months revealed significant reductions in mortality
1.9% vs. 10.1%, p  0.003) and TVR (1.3% vs. 8.1%, p 
.005) also in favor of DES. The stage was set.
In this issue of the Journal, Menichelli et al. (6) in Rome,
taly report the results of the SESAMI (Sirolimus-Eluting
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †University of Texas Health Science Center and Memorial Hermannf
eart and Vascular Institute, Houston, Texas; and ‡Minneapolis Heart Institute at
bbot Northwestern Hospital, Minneapolis, Minnesota.tent Versus Bare-Metal Stent In Acute Myocardial Infarc-
ion) trial. This was a large, single-center trial in which
atients undergoing primary PCI for STEMI were ran-
omly assigned to receive either a DES (Cypher sirolimus-
luting stent [Cordis, Johnson & Johnson, Miami Lakes,
lorida]) or a BMS. The primary end point of the trial was
estenosis determined by angiography at 1 year. Secondary
nd points included target lesion revascularization (TLR),
VR, MACE, and target vessel failure (TVF). Other
ecorded events included death, recurrent infarction, and
tent thrombosis. There were 320 patients who underwent
andom assignment in the SESAMI trial, 160 to each
roup. The SESAMI hypothesis regarding the primary end
oint was proved: binary restenosis on angiography by 1 year
as 9.3% in the DES group and 21.3% in the BMS group
p  0.03). Secondary end points in SESAMI also favored
ES over BMS, with significant reductions in TLR, TVR,
nd MACE. The numbers of occluded culprit vessels at
ollow-up angiography were low and equivalent (2.5% vs.
.7%, p  0.42). Diameter stenosis in the nonoccluded
ulprit vessels was less severe with DES compared with
MS (mean 14% vs. 34%, p  0.001), and late lumen loss
as reduced (mean 0.18 mm vs. 0.85 mm, p  0.001).
imitations of the SESAMI study include the lack of an
ndependent angiographic core laboratory (although angio-
raphic readers were blinded to stent type), and only
ne-half of the enrolled patients had follow-up angiograms
by trial design based on power calculations). High-risk
esions and clinically high-risk patients were excluded. One
ould also argue that the trial was biased in favor of DES by
he use of binary restenosis as the primary end point.
With the publication here of the SESAMI trial, we now
ave 3 moderately large, well-done, randomized trials compar-
ng DES to BMS in the clinical setting of PCI for STEMI. In
rder of publication these are: 1) the TYPHOON (Trial to
ssess the Use of the Cypher Stent in Acute Myocardial
nfarction Treated With Balloon Angioplasty) study (7); 2) the
ASSION (Paclitaxel-Eluting Stent Versus Conventional
tent in Myocardial Infarction With ST-Segment Elevation)
rial (8); and 3) the SESAMI trial. Each was conducted
ndependently in different centers, indeed in different countries.
iven the designs, size, and independence of the 3 trials, we
elieve it is justified to examine their combined data briefly
Table 1). Two of the trials (TYPHOON and SESAMI) used
irolimus-eluting stents, and one (PASSION) used paclitaxel-
luting stents. Notwithstanding the arguments made for and
gainst the pharmacologic properties of the drug agents, the
echanical properties of the stent and catheter devices, and the
roclivities of interventionalists, we do not find that these are
ersuasive enough to prevent a combined analysis. Further-
ore, Hofma et al. (9) compared the outcomes of 136
onsecutive STEMI patients treated with paclitaxel-eluting
tents to 186 consecutive STEMI patients treated with
irolimus-eluting stents (9). No significant differences were
ound in this nonrandomized comparison.
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Editorial Comment May 15, 2007:1931–3A total of 1,624 patients were randomized in these 3
oteworthy trials. Inclusion and exclusion criteria were some-
hat different. The TYPHOON and PASSION trials ex-
luded patients who received any fibrinolytic, whereas the
ESAMI trial included them. Primarily because of this, the
YPHOON and PASSION trials excluded larger proportions
f screened patients than the SESAMI trial did. Thus the
YPHOON trial excluded 65%, the PASSION trial 40%, and
he SESAMI trial 24%. After fibrinolytics the major exclusions
ere for higher-risk features, such as cardiogenic shock, resus-
itation with uncertain neurological status, and high-risk an-
iographic characteristics. The 3 trials therefore are based on
ower-risk infarct patients. Understandably none of the trials
ere powered for the end point of death. Yet when combined
ata are examined, death occurred in 2.7% (22 of 811) of DES
atients and 3.8% (31 of 813) of BMS patients (p  0.264 by
isher exact test) (Table 1). Now this is beginning to get
nteresting.
The 3 trials had different end points. The primary end point
n the TYPHOON trial was TVF, which was a composite
efined as TVR, recurrent infarction, or target-vessel-related
eath at 1 year. The primary end point in the PASSION trial
as the first occurrence of a serious (i.e., major) adverse cardiac
vent (usually termed MACE) at 12 months, including death
rom cardiac causes, recurrent myocardial infarction requiring
ospitalization, and ischemia-driven revascularization of a
arget lesion. Thus, the primary end point of TVF in the
YPHOON trial matches closely the primary end point of
ACE in the PASSION trial. In addition to their primary
nd points, all 3 trials reported rates of TLR, and/or TVR,
nd/or TVF, and/or MACE. For convenience, in Table 1, the
ighest rates of either TLR or TVR, and the highest rates of
VF or MACE, are shown. The stent thrombosis rates in
able 1 are the highest reported at 1 year. The TYPHOON
nd PASSION trials used similar definitions of acute, sub-
cute, and late thrombosis, whereas the SESAMI trial used a
ewer definition of definite/probable/possible. While one
trength of these trials is the uniform 1-year follow-up, even
onger-term results will be important, particularly in regards to
tent thrombosis. For simplicity, the single statistical test
pplied to the categorical data in Table 1 was the Fisher exact
est. Clearly, recurrence after PCI for STEMI, counted as
LR/TVR, or TVF/MACE, is significantly reduced by ap-
roximately 50% with DES compared with BMS.
There was an angiographic substudy in the TYPHOON
rial, with 210 patients (approximately 30%) receiving
ollow-up angiograms at 8 months. And of course, the
rimary end point in the SESAMI trial was angiographic,
ith 50% receiving angiograms at 1 year. Restenosis as a
inary outcome event was reduced by about one-half (10%
s. 20%) based on angiographic data from these 2 studies.
ince it is possible for some skeptics to criticize the low rates
f angiography, the restenosis data do not have to be
onsidered the strongest data contained in these studies,
lthough in our opinion these data are quite good. Theclinical outcome data therefore become paramount.T
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May 15, 2007:1931–3 Editorial CommentThe issue of late (“really late”) stent thrombosis beyond 1 year
s not addressed in these 3 trials. Recently accumulated data appear
o indicate that premature discontinuation of dual antiplatelet
herapy with aspirin and a thienopyridine plays a significant role in
his odd, low-frequency late event. Whether stent thrombosis
eyond a year after PCI for STEMI is greater, the same, or less
ith DES versus BMS remains an open question. The data
xamined here show that out to 1 year the stent thrombosis rates
ppear to be low and equivalent for DES and BMS.
In conclusion, based on available data, the routine im-
lantation of DES is beneficial and can be recommended for
atients undergoing PCI for STEMI.
eprint requests and correspondence: Dr. H. Vernon Anderson,
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